help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heldwein, K. A.
Right arrow Articles by Stenzel-Poore, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heldwein, K. A.
Right arrow Articles by Stenzel-Poore, M. P.

Endocrinology, Vol 137, 3631-3639, Copyright © 1996 by Endocrine Society


ARTICLES

Corticotropin-releasing hormone receptor expression and functional coupling in neonatal cardiac myocytes and AT-1 cells

KA Heldwein, DL Redick, MB Rittenberg, WC Claycomb and MP Stenzel-Poore
Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland 97201, USA.

CRH is the principal mediator of the stress response in mammals. In addition to pituitary and central nervous system effects, peripheral effects of CRH have been observed involving the immune and cardiovascular systems. Two CRH receptor subtypes, CRH-R1 and CRH-R2, have been cloned and show significant amino acid homology (69%), but differ in their tissue distribution. CRH-R1 is expressed predominantly in the brain and pituitary, whereas the CRH-R2 subtype is highly expressed in heart and skeletal muscle. To investigate the role of CRH in cardiac signaling, we analyzed the effect of CRH on freshly isolated neonatal rat cardiomyocytes and murine atrial cardiomyocyte tumor cells, AT-1, which express CRH-R2 messenger RNA. We show that stimulation of these cells with CRH and the CRH-related peptides, sauvagine from frog and urotensin I from fish, elicits large increases in the intracellular level of cAMP. This stimulation is transient, reaching a maximum in 5-15 min in neonatal cardiomyocytes and in 2-4 min in AT-1 cells, followed by a rapid decline. We show that stimulation of AT-1 cells by these peptides is specific for CRH receptors, as the CRH antagonist, alpha-helical CRH-(9-41) inhibits cAMP increases. Furthermore, we show that CRH, sauvagine, and urotensin I stimulations are dose dependent in both neonatal cardiomyocytes and AT-1 cells. Sauvagine and urotensin I are more potent than CRH at stimulating an increase in intracellular cAMP in neonatal cardiomyocytes (EC50 = 1.74, 2.61, 6.42 nM, respectively) and AT-1 cells (EC50 = 16.2, 15.8, and 149 nM, respectively). This rank order is consistent with that previously demonstrated in CRH-R2-transfected HEK293 cells and parallels the in vivo vasodilatory activity of these peptides. In summary, this is the first evidence that CRH, sauvagine, and urotensin I act directly on cardiac myocytes to stimulate increases in intracellular cAMP, presumably through CRH-R2. In addition, these results indicate that cardiac myocytes may be an informative in vitro model to investigate the effects of CRH and its role in the cardiovascular response to stress.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. T. Hinkle, E. Donnelly, D. B. Cody, S. Samuelsson, J. S. Lange, M. B. Bauer, M. Tarnopolsky, R. J. Sheldon, S. C. Coste, E. Tobar, et al.
Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E889 - E898.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Huang, F. L. Chan, C.-W. Lau, S.-Y. Tsang, Z.-Y. Chen, G.-W. He, and X. Yao
Roles of cyclic AMP and Ca2+-activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary artery
Cardiovasc Res, March 1, 2003; 57(3): 824 - 833.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. C. Coste, K. A. Heldwein, S. L. Stevens, E. Tobar-Dupres, and M. P. Stenzel-Poore
IL-1{alpha} and TNF{alpha} Down-Regulate CRH Receptor-2 mRNA Expression in the Mouse Heart
Endocrinology, August 1, 2001; 142(8): 3537 - 3545.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
D. G. Parkes and C. N. May
Urocortin: A Novel Player in Cardiac Control
Physiology, October 1, 2000; 15(5): 264 - 268.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Slominski, J. Wortsman, T. Luger, R. Paus, and S. Solomon
Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress
Physiol Rev, July 1, 2000; 80(3): 979 - 1020.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. K. Brar, A. K. Jonassen, A. Stephanou, G. Santilli, J. Railson, R. A. Knight, D. M. Yellon, and D. S. Latchman
Urocortin Protects against Ischemic and Reperfusion Injury via a MAPK-dependent Pathway
J. Biol. Chem., March 17, 2000; 275(12): 8508 - 8514.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. H. PERRIN and W. W. VALE
Corticotropin Releasing Factor Receptors and Their Ligand Family
Ann. N.Y. Acad. Sci., October 20, 1999; 885(1): 312 - 328.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Slominski, G. Ermak, J. E. Mazurkiewicz, J. Baker, and J. Wortsman
Characterization of Corticotropin-Releasing Hormone (CRH) in Human Skin
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1020 - 1024.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society